Histocytologic Criteria of Adenocarcinoma In Situ of the Esophagus

2002 ◽  
pp. 31-36
Author(s):  
Carlos A. Rubio
Keyword(s):  
Adenocarcinoma In Situ

Isolated Ovarian Recurrence of Endocervical Adenocarcinoma In Situ

2016 ◽  
Vol 32 (3) ◽  
pp. 189-192 ◽  
Author(s):  
Elena B. Pereira ◽  
Lena El Hachem ◽  
Mazdak Momeni ◽  
Richard Eisen ◽  
Herbert Gretz
Keyword(s):  
Adenocarcinoma In Situ ◽  
Endocervical Adenocarcinoma

Cervical Cytology Screening History of Women Diagnosed with Adenocarcinoma in Situ of the Cervix

2004 ◽  
Vol 48 (5) ◽  
pp. 595-600 ◽  
Author(s):  
Heather Mitchell ◽  
Jane Hocking ◽  
Marion Saville
Keyword(s):  
Cervical Cytology ◽  
Adenocarcinoma In Situ ◽  
History Of ◽  
Cytology Screening ◽  
Screening History

Pulmonary Adenocarcinoma In Situ: A Transformation of Terms and Tissue

CHEST Journal ◽  
2013 ◽  
Vol 144 (4) ◽  
pp. 638A
Author(s):  
Tomer Pelleg ◽  
Moises Cossio ◽  
A. Lukas Loschner
Keyword(s):  
Pulmonary Adenocarcinoma ◽  
Adenocarcinoma In Situ

Margin status post cervical conization predicts residual adenocarcinoma in situ and occult adenocarcinoma

2021 ◽  
Vol 162 ◽  
pp. S203-S204
Author(s):  
Linda Hong ◽  
Sandy Huynh ◽  
Joy Kim ◽  
Laura Denham ◽  
Yevgeniya Ioffe
Keyword(s):  
Margin Status ◽  
Adenocarcinoma In Situ ◽  
Cervical Conization

The Pittsburgh Cervical Cancer Screening Model: A Risk Assessment Tool

2010 ◽  
Vol 134 (5) ◽  
pp. 744-750
Author(s):  
R. Marshall Austin ◽  
Agnieszka Onisko ◽  
Marek J. Druzdzel
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Disease Risk ◽  
Hpv Vaccination ◽  
Dynamic Bayesian Network ◽  
Adenocarcinoma In Situ ◽  
Test Results ◽  
Hpv Test

Abstract Context.—Evaluation of cervical cancer screening has grown increasingly complex with the introduction of human papillomavirus (HPV) vaccination and newer screening technologies approved by the US Food and Drug Administration. Objective.—To create a unique Pittsburgh Cervical Cancer Screening Model (PCCSM) that quantifies risk for histopathologic cervical precancer (cervical intraepithelial neoplasia [CIN] 2, CIN3, and adenocarcinoma in situ) and cervical cancer in an environment predominantly using newer screening technologies. Design.—The PCCSM is a dynamic Bayesian network consisting of 19 variables available in the laboratory information system, including patient history data (most recent HPV vaccination data), Papanicolaou test results, high-risk HPV results, procedure data, and histopathologic results. The model's graphic structure was based on the published literature. Results from 375 441 patient records from 2005 through 2008 were used to build and train the model. Additional data from 45 930 patients were used to test the model. Results.—The PCCSM compares risk quantitatively over time for histopathologically verifiable CIN2, CIN3, adenocarcinoma in situ, and cervical cancer in screened patients for each current cytology result category and for each HPV result. For each current cytology result, HPV test results affect risk; however, the degree of cytologic abnormality remains the largest positive predictor of risk. Prior history also alters the CIN2, CIN3, adenocarcinoma in situ, and cervical cancer risk for patients with common current cytology and HPV test results. The PCCSM can also generate negative risk projections, estimating the likelihood of the absence of histopathologic CIN2, CIN3, adenocarcinoma in situ, and cervical cancer in screened patients. Conclusions.—The PCCSM is a dynamic Bayesian network that computes quantitative cervical disease risk estimates for patients undergoing cervical screening. Continuously updatable with current system data, the PCCSM provides a new tool to monitor cervical disease risk in the evolving postvaccination era.

A Clinicopathological Study of Small Lung Adenocarcinoma 1 cm or Less in Size: Emphasis on Histological Subtypes Associated With Lymph Node Metastasis and Recurrence

2017 ◽  
Vol 26 (1) ◽  
pp. 4-11 ◽  
Author(s):  
Wei Zhao ◽  
Hui Wang ◽  
Jun Xie ◽  
Bo Tian
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Lung Adenocarcinoma ◽  
Who Classification ◽  
Limited Resection ◽  
Adenocarcinoma In Situ ◽  
Invasive Adenocarcinoma ◽  
Node Metastasis ◽  
Minimally Invasive Adenocarcinoma

Background. The aim of this study was to assess the prognostic significance of the newly proposed 2015 World Health Organization (WHO) lung adenocarcinoma classification for patients undergoing resection for small (≤1 cm) lung adenocarcinoma. We also investigated whether lobectomy offers prognostic advantage over limited resection for this category of tumors. Methods. A retrospective study of resected pulmonary adenocarcinomas (n = 83) in sizes 1 cm or less was carried out in which comprehensive histologic subtyping was assessed according to the 2015 WHO classification on all consecutive patients who underwent lobectomy or limited resection between 1998 and 2012. Correlation between clinicopathologic parameters and the difference in recurrence between lobectomy and limited resection group was evaluated. Results. Our data show that the proposed 2015 WHO classification identifies histological subsets of small lung adenocarcinomas with significant differences in prognosis. No recurrence was noted for patients with adenocarcinoma in situ and minimally invasive adenocarcinoma. Invasive adenocarcinomas displayed high heterogeneity and the presence of micropapillary component of 5% or greater in adenocarcinomas was significantly related to lymph node involvement and recurrence ( P < .001). Stage IA patients who underwent limited resection had a higher risk of recurrence than did those treated by lobectomy ( P < .05). Conclusions. Application of the 2015 WHO classification identifies patients with adenocarcinoma in situ and minimally invasive adenocarcinoma had excellent prognosis. Micropapillary pattern was associated with high risk of lymph node metastasis and recurrence.

scholarly journals Cytology of adenocarcinoma in situ of the uterine cervix - A caryometric study.

1986 ◽  
Vol 25 (1) ◽  
pp. 82-86
Author(s):  
Ichiro NASU ◽  
Yukinori YONEMOTO ◽  
Hisashi HIGASHIIWAI ◽  
Setsuko TAKEDA ◽  
Susumu SUZUKA ◽  
...  
Keyword(s):  
Uterine Cervix ◽  
Adenocarcinoma In Situ
Sign in / Sign up

Export Citation Format

Share Document